Download PDF
Thorac Cardiovasc Surg 2015; 63(08): 636-646
DOI: 10.1055/s-0035-1546296
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Bleeding and Thrombotic Events in Patients Undergoing Mechanical Circulatory Support: A Review of Literature

Mate Petricevic
1   Department of Cardiac Surgery, University of Zagreb School of Medicine, University Hospital Center Zagreb, Croatia
,
Davor Milicic
2   Department of Cardiovascular Disease, University of Zagreb School of Medicine, University Hospital Center Zagreb, Croatia
,
Marko Boban
3   Department of Cardiology, University Hospital “Thalassotherapia Opatija”, Medical School University of Osijek and Rijeka, Osijek, Croatia
,
Martina Zrno Mihaljevic
1   Department of Cardiac Surgery, University of Zagreb School of Medicine, University Hospital Center Zagreb, Croatia
,
Zeljko Baricevic
2   Department of Cardiovascular Disease, University of Zagreb School of Medicine, University Hospital Center Zagreb, Croatia
,
Kresimir Kolic
4   Department of Radiology and Medical Diagnostics, University of Split School of Medicine, University Hospital Center Split, Split, Croatia
,
Kresimir Dolic
4   Department of Radiology and Medical Diagnostics, University of Split School of Medicine, University Hospital Center Split, Split, Croatia
,
Lucija Konosic
1   Department of Cardiac Surgery, University of Zagreb School of Medicine, University Hospital Center Zagreb, Croatia
,
Tomislav Kopjar
1   Department of Cardiac Surgery, University of Zagreb School of Medicine, University Hospital Center Zagreb, Croatia
,
Bojan Biocina
1   Department of Cardiac Surgery, University of Zagreb School of Medicine, University Hospital Center Zagreb, Croatia
› Author Affiliations
Further Information

Publication History

06 September 2014

02 January 2015

Publication Date:
05 March 2015 (online)

    Permissions and Reprints All articles of this category

Abstract

Bleeding and thrombotic events are among the most common complications detected in patients with mechanical circulatory support (MCS). Herein, we reviewed the available evidence on the prevalence, etiology, and management of bleeding and thrombotic events in patients following MCS procedures, such as implantation of both intra- and paracorporeal devices that generate either pulsatile or nonpulsatile flow. Extracorporeal life support procedures providing support to the failing heart and lungs were also reviewed. Most bleeding and thromboembolic events occur despite appropriate hemostatic and anticoagulation management based on conventional coagulation laboratory parameters. Prevalence of bleeding events in this population ranges between 5 and 81%. Wide range in prevalence of bleeding reported in literature may be explained by different devices with different anticoagulation protocols being used, as well as different definitions of bleeding outcomes. Although bleeding events are more common than thromboembolic events, the consequences of thrombotic events are often detrimental. Management of bleeding events remains challenging and measures to prevent and treat bleeding events are often followed by thromboembolic events. Therefore, a personalized approach based on point-of-care hemostatic tests and adjusted to device type and patient comorbidities is therefore warranted. To provide advanced understanding of hemostatic disturbances during MCS, prospective trials focused on bleeding and thromboembolic events as primary endpoints should be conducted. Better understanding of the underlying pathophysiology and a shift towards a personalized approach based on functional point-of-care hemostatic properties assessment may provide more favorable clinical outcomes. This should, however, be coupled with further technological improvements providing better device surface hemocompatibility as interaction between blood and device surface affects the hemostatic equilibrium.

Keywords

mechanical circulatory support - hemorrhage - thrombosis - ventricular assist device - VAD thrombosis - extracorporeal life support - postoperative bleeding - bleeding management
 

  • References

  • 1 Smedira NG, Hoercher KJ, Lima B , et al. Unplanned hospital readmissions after HeartMate II implantation: frequency, risk factors, and impact on resource use and survival. JACC Heart Fail 2013; 1 (1) 31-39
    CrossrefPubMedGoogle Scholar
  • 2 Esper SA, Levy JH, Waters JH, Welsby IJ. Extracorporeal membrane oxygenation in the adult: a review of anticoagulation monitoring and transfusion. Anesth Analg 2014; 118 (4) 731-743
    CrossrefPubMedGoogle Scholar
  • 3 Feldman D, Pamboukian SV, Teuteberg JJ , et al; International Society for Heart and Lung Transplantation. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant 2013; 32 (2) 157-187
    CrossrefPubMedGoogle Scholar
  • 4 Petricevic M, Kopjar T, Biocina B , et al. The predictive value of platelet function point-of-care tests for postoperative blood loss and transfusion in routine cardiac surgery: a systematic review. Thorac Cardiovasc Surg 2015; 63 (1) 2-20
    PubMedGoogle Scholar
  • 5 Petricevic M, Biocina B, Safradin I, Gasparovic H. Preoperative aspirin discontinuation management and bleeding outcome in elective coronary artery surgery. Thorac Cardiovasc Surg 2013; 61 (8) 731-732
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Petricevic M, Biocina B, Milicic D, Lekic A, Safradin I, Gasparovic H. Multiple electrode aggregometry and prediction of bleeding and transfusion outcomes in adult cardiac surgery patients: methodological challenges and opportunities for future. Thorac Cardiovasc Surg 2013; 61 (8) 744-745
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Petricevic M, Biocina B, Milicic D , et al. Bleeding risk assessment using whole blood impedance aggregometry and rotational thromboelastometry in patients following cardiac surgery. J Thromb Thrombolysis 2013; 36 (4) 514-526
    CrossrefPubMedGoogle Scholar
  • 8 Petricevic M, Biocina B, Milicic D , et al. Bleeding risk assessment using multiple electrode aggregometry in patients following coronary artery bypass surgery. J Thromb Thrombolysis 2013; 35 (1) 31-40
    CrossrefPubMedGoogle Scholar
  • 9 Petricevic M, Biocina B, Milicic D , et al. Activated coagulation time vs. intrinsically activated modified rotational thromboelastometry in assessment of hemostatic disturbances and blood loss after protamine administration in elective cardiac surgery: analysis from the clinical trial (NCT01281397). J Cardiothorac Surg 2014; 9: 129
    CrossrefPubMedGoogle Scholar
  • 10 Paluszkiewicz L, Gürsoy D, Spiliopoulos S , et al. HeartMate II ventricular assist device thrombosis-an echocardiographic approach to diagnosis: can Doppler evaluation of flow be useful?. J Am Soc Echocardiogr 2011; 24 (3) 350.e1-350.e4
    CrossrefPubMedGoogle Scholar
  • 11 Estep JD, Vivo RP, Cordero-Reyes AM , et al. A simplified echocardiographic technique for detecting continuous-flow left ventricular assist device malfunction due to pump thrombosis. J Heart Lung Transplant 2014; 33 (6) 575-586
    CrossrefPubMedGoogle Scholar
  • 12 Slaughter MS, Rogers JG, Milano CA , et al; HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361 (23) 2241-2251
    CrossrefPubMedGoogle Scholar
  • 13 Crow S, John R, Boyle A , et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg 2009; 137 (1) 208-215
    CrossrefPubMedGoogle Scholar
  • 14 Genovese EA, Dew MA, Teuteberg JJ , et al. Incidence and patterns of adverse event onset during the first 60 days after ventricular assist device implantation. Ann Thorac Surg 2009; 88 (4) 1162-1170
    CrossrefPubMedGoogle Scholar
  • 15 Morrison KA, Jorde UP, Garan AR, Takayama H, Naka Y, Uriel N. Acquired von Willebrand disease during CentriMag support is associated with high prevalence of bleeding during support and after transition to heart replacement therapy. ASAIO J 2014; 60 (2) 241-242
    CrossrefPubMedGoogle Scholar
  • 16 Uriel N, Pak SW, Jorde UP , et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol 2010; 56 (15) 1207-1213
    CrossrefPubMedGoogle Scholar
  • 17 Suarez J, Patel CB, Felker GM, Becker R, Hernandez AF, Rogers JG. Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. Circ Heart Fail 2011; 4 (6) 779-784
    CrossrefPubMedGoogle Scholar
  • 18 Eckman PM, John R. Bleeding and thrombosis in patients with continuous-flow ventricular assist devices. Circulation 2012; 125 (24) 3038-3047
    CrossrefPubMedGoogle Scholar
  • 19 Dassanayaka S, Slaughter MS, Bartoli CR. Mechanistic pathway(s) of acquired von Willebrand syndrome with a continuous-flow ventricular assist device: in vitro findings. ASAIO J 2013; 59 (2) 123-129
    CrossrefPubMedGoogle Scholar
  • 20 Heilmann C, Geisen U, Beyersdorf F , et al. Acquired Von Willebrand syndrome is an early-onset problem in ventricular assist device patients. Eur J Cardiothorac Surg 2011; 40 (6) 1328-1333 , discussion 1233
    PubMedGoogle Scholar
  • 21 Geisen U, Heilmann C, Beyersdorf F , et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg 2008; 33 (4) 679-684
    CrossrefPubMedGoogle Scholar
  • 22 Starke RD, Ferraro F, Paschalaki KE , et al. Endothelial von Willebrand factor regulates angiogenesis. Blood 2011; 117 (3) 1071-1080
    CrossrefPubMedGoogle Scholar
  • 23 Görlinger K, Bergmann L, Dirkmann D. Coagulation management in patients undergoing mechanical circulatory support. Best Pract Res Clin Anaesthesiol 2012; 26 (2) 179-198
    CrossrefPubMedGoogle Scholar
  • 24 Gödje O, Gallmeier U, Schelian M, Grünewald M, Mair H. Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thorac Cardiovasc Surg 2006; 54 (1) 26-33
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Korte W. F. XIII in perioperative coagulation management. Best Pract Res Clin Anaesthesiol 2010; 24 (1) 85-93
    CrossrefPubMedGoogle Scholar
  • 26 Pagani FD, Miller LW, Russell SD , et al; HeartMate II Investigators. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 2009; 54 (4) 312-321
    CrossrefPubMedGoogle Scholar
  • 27 Shrode CW, Draper KV, Huang RJ , et al. Significantly higher rates of gastrointestinal bleeding and thromboembolic events with left ventricular assist devices. Clin Gastroenterol Hepatol 2014; 12 (9) 1461-1467
    CrossrefPubMedGoogle Scholar
  • 28 John R, Kamdar F, Liao K , et al. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device. J Thorac Cardiovasc Surg 2008; 136 (5) 1318-1323
    CrossrefPubMedGoogle Scholar
  • 29 Slaughter MS. Hematologic effects of continuous flow left ventricular assist devices. J Cardiovasc Transl Res 2010; 3 (6) 618-624
    CrossrefPubMedGoogle Scholar
  • 30 Strüber M, Sander K, Lahpor J , et al. HeartMate II left ventricular assist device: early European experience. Eur J Cardiothorac Surg 2008; 34 (2) 289-294
    CrossrefPubMedGoogle Scholar
  • 31 John R, Kamdar F, Liao K, Colvin-Adams M, Boyle A, Joyce L. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy. Ann Thorac Surg 2008; 86 (4) 1227-1234 , discussion 1234–1235
    CrossrefPubMedGoogle Scholar
  • 32 Klovaite J, Gustafsson F, Mortensen SA, Sander K, Nielsen LB. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol 2009; 53 (23) 2162-2167
    CrossrefPubMedGoogle Scholar
  • 33 Boyle AJ, Russell SD, Teuteberg JJ , et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant 2009; 28 (9) 881-887
    CrossrefPubMedGoogle Scholar
  • 34 Litzler PY, Smail H, Barbay V , et al. Is anti-platelet therapy needed in continuous flow left ventricular assist device patients? A single-centre experience. Eur J Cardiothorac Surg 2014; 45 (1) 55-59 , discussion 59–60
    CrossrefPubMedGoogle Scholar
  • 35 Thunberg CA, Gaitan BD, Arabia FA, Cole DJ, Grigore AM. Ventricular assist devices today and tomorrow. J Cardiothorac Vasc Anesth 2010; 24 (4) 656-680
    CrossrefPubMedGoogle Scholar
  • 36 Mittermayr M, Margreiter J, Velik-Salchner C , et al. Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem): an in vitro study. Br J Anaesth 2005; 95 (3) 310-316
    CrossrefPubMedGoogle Scholar
  • 37 Gasparovic H, Petricevic M, Kopjar T, Djuric Z, Svetina L, Biocina B. Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting. Am J Cardiol 2014; 113 (10) 1660-1667
    CrossrefPubMedGoogle Scholar
  • 38 Gasparovic H, Petricevic M, Biocina B. Management of antiplatelet therapy resistance in cardiac surgery. J Thorac Cardiovasc Surg 2014; 147 (3) 855-862
    CrossrefPubMedGoogle Scholar
  • 39 Slaughter MS, Pagani FD, Rogers JG , et al; HeartMate II Clinical Investigators. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant 2010; 29 (4, Suppl): S1-S39
    CrossrefPubMedGoogle Scholar
  • 40 Majeed F, Kop WJ, Poston RS, Kallam S, Mehra MR. Prospective, observational study of antiplatelet and coagulation biomarkers as predictors of thromboembolic events after implantation of ventricular assist devices. Nat Clin Pract Cardiovasc Med 2009; 6 (2) 147-157
    CrossrefPubMedGoogle Scholar
  • 41 Matsubayashi H, Fastenau DR, McIntyre JA. Changes in platelet activation associated with left ventricular assist system placement. J Heart Lung Transplant 2000; 19 (5) 462-468
    CrossrefPubMedGoogle Scholar
  • 42 Bonaros N, Mueller MR, Salat A , et al. Extensive coagulation monitoring in patients after implantation of the MicroMed Debakey continuous flow axial pump. ASAIO J 2004; 50 (5) 424-431
    CrossrefPubMedGoogle Scholar
  • 43 Zimmermann N, Kurt M, Wenk A, Winter J, Gams E, Hohlfeld T. Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting?. Eur J Cardiothorac Surg 2005; 27 (4) 606-610
    CrossrefPubMedGoogle Scholar
  • 44 Börgermann J, Kanashnik A, Sossdorf M, Gummert J, Lösche W. Individual variability of response and non-response to acetyl salicylic acid after cardiac surgery. Platelets 2010; 21 (8) 610-615
    CrossrefPubMedGoogle Scholar
  • 45 Petricevic M, Biocina B, Konosic S, Kopjar T, Kunac N, Gasparovic H. Assessment of platelet function by whole blood impedance aggregometry in coronary artery bypass grafting patients on acetylsalicylic acid treatment may prompt a switch to dual antiplatelet therapy. Heart Vessels 2013; 28 (1) 57-65
    CrossrefPubMedGoogle Scholar
  • 46 Genovese EA, Dew MA, Teuteberg JJ , et al. Early adverse events as predictors of 1-year mortality during mechanical circulatory support. J Heart Lung Transplant 2010; 29 (9) 981-988
    CrossrefPubMedGoogle Scholar
  • 47 Bartoli CR, Ailawadi G, Kern JA. Diagnosis, nonsurgical management, and prevention of LVAD thrombosis. J Card Surg 2014; 29 (1) 83-94
    CrossrefPubMedGoogle Scholar
  • 48 Tan KT, Lip GY. Red vs white thrombi: treating the right clot is crucial. Arch Intern Med 2003; 163 (20) 2534-2535 , author reply 2535
    CrossrefPubMedGoogle Scholar
  • 49 Stulak JM, Deo S, Schirger J , et al. Preoperative atrial fibrillation increases risk of thromboembolic events after left ventricular assist device implantation. Ann Thorac Surg 2013; 96 (6) 2161-2167
    CrossrefPubMedGoogle Scholar
  • 50 Petricević M, Biocina B, Konosić S , et al. Definition of acetylsalicylic acid resistance using whole blood impedance aggregometry in patients undergoing coronary artery surgery. Coll Antropol 2013; 37 (3) 833-839
    PubMedGoogle Scholar
  • 51 Zimmermann N, Kienzle P, Weber AA , et al. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 121 (5) 982-984
    CrossrefPubMedGoogle Scholar
  • 52 Zimmermann N, Kurt M, Winter J, Gams E, Wenzel F, Hohlfeld T. Detection and duration of aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2008; 135 (4) 947-948
    CrossrefPubMedGoogle Scholar
  • 53 Kempfert J, Anger K, Rastan A , et al. Postoperative development of aspirin resistance following coronary artery bypass. Eur J Clin Invest 2009; 39 (9) 769-774
    CrossrefPubMedGoogle Scholar
  • 54 Houël R, Mazoyer E, Boval B , et al. Platelet activation and aggregation profile in prolonged external ventricular support. J Thorac Cardiovasc Surg 2004; 128 (2) 197-202
    CrossrefPubMedGoogle Scholar
  • 55 Bednar F, Osmancik P, Hlavicka J, Jedlickova V, Paluch Z, Vanek T. Aspirin is insufficient in inhibition of platelet aggregation and thromboxane formation early after coronary artery bypass surgery. J Thromb Thrombolysis 2009; 27 (4) 394-399
    CrossrefPubMedGoogle Scholar
  • 56 Houël R, Mazoyer E, Kirsch M, Boval B, Drouet L, Loisance DY. Resistance to aspirin after external ventricular assist device implantation. J Thorac Cardiovasc Surg 2003; 126 (5) 1636-1637
    CrossrefPubMedGoogle Scholar
  • 57 Aissaoui N, Hakim-Meibodi K, Morshuis M, Gummert J. Recurrent thrombosis after mechanical circulatory support. Interact Cardiovasc Thorac Surg 2012; 14 (5) 668-669
    CrossrefPubMedGoogle Scholar
  • 58 Doepp F, Sanad W, Schreiber SJ, Baumann G, Borges AC. Left ventricular apical thrombus after systemic thrombolysis with recombinant tissue plasminogen activator in a patient with acute ischemic stroke. Cardiovasc Ultrasound 2005; 3: 14
    CrossrefPubMedGoogle Scholar
  • 59 Leontiadis E, Koertke H, Bairaktaris A, Koerfer R. Thrombosis of the ascending aorta during mechanical circulatory support in a patient with cardiogenic shock. Interact Cardiovasc Thorac Surg 2010; 11 (4) 510-511
    CrossrefPubMedGoogle Scholar
  • 60 Meyer AL, Malehsa D, Kuehn C , et al. HeartMate II implantation in patients with heparin-induced thrombocytopenia type II. Ann Thorac Surg 2009; 88 (2) 674-675
    CrossrefPubMedGoogle Scholar
  • 61 Nocera P, Thiranos JC, Steib A, Morelli U. Heparin induced thrombocytopenia in patients with ventricular assistance device bridge-to-transplantation. A case series. Minerva Cardioangiol 2008; 56 (6) 697-701
    PubMedGoogle Scholar
  • 62 Webb DP, Warhoover MT, Eagle SS, Greelish JP, Zhao DX, Byrne JG. Argatroban in short-term percutaneous ventricular assist subsequent to heparin-induced thrombocytopenia. J Extra Corpor Technol 2008; 40 (2) 130-134
    PubMedGoogle Scholar
  • 63 Voeller RK, Melby SJ, Grizzell BE, Moazami N. Novel use of plasmapheresis in a patient with heparin-induced thrombocytopenia requiring urgent insertion of a left ventricular assist device under cardiopulmonary bypass. J Thorac Cardiovasc Surg 2010; 140 (3) e56-e58
    CrossrefPubMedGoogle Scholar
  • 64 Zucker MJ, Sabnani I, Baran DA, Balasubramanian S, Camacho M. Cardiac transplantation and/or mechanical circulatory support device placement using heparin anti-coagulation in the presence of acute heparin-induced thrombocytopenia. J Heart Lung Transplant 2010; 29 (1) 53-60
    CrossrefPubMedGoogle Scholar
  • 65 Potapov EV, Stepanenko A, Krabatsch T, Hetzer R. Managing long-term complications of left ventricular assist device therapy. Curr Opin Cardiol 2011; 26 (3) 237-244
    CrossrefPubMedGoogle Scholar
  • 66 Delgado III R, Frazier OH, Myers TJ , et al. Direct thrombolytic therapy for intraventricular thrombosis in patients with the Jarvik 2000 left ventricular assist device. J Heart Lung Transplant 2005; 24 (2) 231-233
    CrossrefPubMedGoogle Scholar
  • 67 Rothenburger M, Wilhelm MJ, Hammel D , et al. Treatment of thrombus formation associated with the MicroMed DeBakey VAD using recombinant tissue plasminogen activator. Circulation 2002; 106 (12) (Suppl. 01) I189-I192
    PubMedGoogle Scholar
  • 68 Thomas MD, Wood C, Lovett M, Dembo L, O'Driscoll G. Successful treatment of rotary pump thrombus with the glycoprotein IIb/IIIa inhibitor tirofiban. J Heart Lung Transplant 2008; 27 (8) 925-927
    CrossrefPubMedGoogle Scholar
  • 69 Paparella D, Brister SJ, Buchanan MR. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 2004; 30 (10) 1873-1881
    CrossrefPubMedGoogle Scholar
  • 70 Stulak JM, Lee D, Haft JW , et al. Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device. J Heart Lung Transplant 2014; 33 (1) 60-64
    CrossrefPubMedGoogle Scholar
  • 71 Schmid C, Hammel D, Deng MC , et al. Ambulatory care of patients with left ventricular assist devices. Circulation 1999; 100 (19, Suppl): II224-II228
    PubMedGoogle Scholar
  • 72 Valarche V, Desconclois C, Boutekedjiret T, Dreyfus M, Proulle V. Multiplate whole blood impedance aggregometry: a new tool for von Willebrand disease. J Thromb Haemost 2011; 9 (8) 1645-1647
    CrossrefPubMedGoogle Scholar
  • 73 Weiss DR, Strasser EF, Ringwald J, Zimmermann R, Eckstein R. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level. Clin Lab 2012; 58 (11–12) 1203-1209
    PubMedGoogle Scholar
  • 74 Lev EI, Ramchandani M, Garg R , et al. Response to aspirin and clopidogrel in patients scheduled to undergo cardiovascular surgery. J Thromb Thrombolysis 2007; 24 (1) 15-21
    CrossrefPubMedGoogle Scholar
  • 75 Koessler J, Kobsar AL, Rajkovic MS , et al. The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y12 receptor inhibition. Platelets 2011; 22 (1) 20-27
    PubMedGoogle Scholar
  • 76 Görlinger K, Fries D, Dirkmann D, Weber CF, Hanke AA, Schöchl H. Reduction of fresh frozen plasma requirements by perioperative point-of-care coagulation management with early calculated goal-directed therapy. Transfus Med Hemother 2012; 39 (2) 104-113
    CrossrefPubMedGoogle Scholar
  • 77 Görlinger K, Dirkmann D, Hanke AA , et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. Anesthesiology 2011; 115 (6) 1179-1191
    CrossrefPubMedGoogle Scholar
  • 78 Park SJ, Tector A, Piccioni W , et al. Left ventricular assist devices as destination therapy: a new look at survival. J Thorac Cardiovasc Surg 2005; 129 (1) 9-17
    CrossrefPubMedGoogle Scholar
  • 79 Portner PM, Jansen PG, Oyer PE, Wheeldon DR, Ramasamy N. Improved outcomes with an implantable left ventricular assist system: a multicenter study. Ann Thorac Surg 2001; 71 (1) 205-209
    CrossrefPubMedGoogle Scholar
  • 80 Strauch JT, Spielvogel D, Haldenwang PL , et al. Recent improvements in outcome with the Novacor left ventricular assist device. J Heart Lung Transplant 2003; 22 (6) 674-680
    CrossrefPubMedGoogle Scholar
  • 81 Long JW, Kfoury AG, Slaughter MS , et al. Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study. Congest Heart Fail 2005; 11 (3) 133-138
    CrossrefPubMedGoogle Scholar
  • 82 Lietz K, Long JW, Kfoury AG , et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 2007; 116 (5) 497-505
    CrossrefPubMedGoogle Scholar
  • 83 Long JW, Healy AH, Rasmusson BY , et al. Improving outcomes with long-term “destination” therapy using left ventricular assist devices. J Thorac Cardiovasc Surg 2008; 135 (6) 1353-1360 , discussion 1360–1361
    CrossrefPubMedGoogle Scholar
  • 84 Petricevic M, Biocina B, Lekic A, Ivancan V, Milicic D. Can we predict excessive bleeding using point-of-care assays?. Int J Lab Hematol 2014; 36 (4) 496-498
    CrossrefPubMedGoogle Scholar
  • 85 Petricevic M, Biocina B, Habekovic R, Milicic D. Blood transfusion in coronary artery surgery: focus on modifiable risk factors. Eur J Cardiothorac Surg 2013; 44 (4) 775-776
    CrossrefPubMedGoogle Scholar
  • 86 Spiess BD, Gillies BS, Chandler W, Verrier E. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 1995; 9 (2) 168-173
    CrossrefPubMedGoogle Scholar
  • 87 John R, Lietz K, Schuster M , et al. Immunologic sensitization in recipients of left ventricular assist devices. J Thorac Cardiovasc Surg 2003; 125 (3) 578-591
    CrossrefPubMedGoogle Scholar
  • 88 Kirkpatrick JN, Wiegers SE, Lang RM. Left ventricular assist devices and other devices for end-stage heart failure: utility of echocardiography. Curr Cardiol Rep 2010; 12 (3) 257-264
    CrossrefPubMedGoogle Scholar
  • 89 Himmelreich G, Ullmann H, Riess H , et al. Pathophysiologic role of contact activation in bleeding followed by thromboembolic complications after implantation of a ventricular assist device. ASAIO J 1995; 41 (3) M790-M794
    CrossrefPubMedGoogle Scholar
  • 90 Sin DC, Kei HL, Miao X. Surface coatings for ventricular assist devices. Expert Rev Med Devices 2009; 6 (1) 51-60
    CrossrefPubMedGoogle Scholar